July 21, 2024
Nanobodies Market

The Emerging Nanobodies Market Primed For Exponential Growth Over The Decade

Market Overview:

The nanobodies market is estimated to be valued at US$ 368.6 Million In 2023 and is expected to exhibit a CAGR of 24.1% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights. Nanobodies, also known as single domain antibody fragments or VHHs, are gaining popularity due to their smaller molecular size, high stability, specificity and affinity to targets. These properties enable nanobodies to be used for therapeutic interventions and diagnostic imaging applications.

Market Dynamics:

The key drivers fueling the growth of the nanobodies market include rising investments in research & development activities for developing nanobody-based drugs and increasing preference for nanobodies over conventional antibody fragments due to their several advantages. For instance, nanobodies exhibit higher tissue penetration capabilities as compared to conventional antibodies due to their smaller size. Their high stability allows nanobodies to withstand harsh conditions like heat and harsh solvents. This has increased their potential applications across various disease areas like oncology, infectious diseases, cardiovascular disorders and others.

Market Trends:

The Nanobodies Market is witnessing high growth due to increasing investment in healthcare research and drug development activities across biotechnology and pharmaceutical industries. Nanobodies offer significant advantages over monoclonal antibodies due to their small size, high stability and specificity. Their ability to interact with epitopes that are difficult to access with conventional antibodies is accelerating research in drug discovery.

SWOT Analysis:

Strengths: Nanobodies have high tissue penetration capabilities and binding affinities. They can be produced through microbial systems at lower costs.
Weaknesses: Downstream processing challenges remain during large scale manufacturing of nanobodies. Clinical validation still pending for most applications.
Opportunities: Wide application areas in diagnostics, therapeutics and research activities. Growing R&D in disease-specific nanobody drugs.
Threats: Stringent regulatory guidelines for clinical trials and approvals. Competition from other novel drug formats.

Key Takeaways:

The global nanobodies market is expected to witness high growth, exhibiting CAGR of 24.1% over the forecast period, due to increasing R&D investment in antibody therapeutics.

The market size for nanobodies was valued at US$ 368.6 Million In 2023 and is estimated to reach Over US$ 3 Billion By 2030. North America dominates the nanobodies market currently due to presence of major players and high adoption in research applications.

Key players operating in the nanobodies market are Merck KGaA, Sanofi, AlpalifeB Inc, GenScript, Novartis International AG, Taisho Pharmaceutical Holdings Co., Ltd., Sino Biological, Inc., GeneMedi, Biocytogen, Abnova Corporation, NanoTag Biotechnologies, Avillion LLP, Capra Science, Numab Therapeutics, CUSABIO TECHNOLOGY LLC, Proteintech Group, Inc., GT Biopharma, Inc., Confo Therapeutics, R&D Systems, Inc., Abcepta Biotech Ltd. Co.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it